Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.57 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.49 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18381361 | 0.84 | CYP3A4 (0.58) | QPCTQPCTLHRH3MEN1KMT2A | |
| SCHEMBL27303234 | 0.83 | HRH3 (0.50) | QPCTQPCTLHRH3HRH4TBXAS1 | |
| SCHEMBL4251397 | 0.82 | ALDH1A1 (0.61) | QPCTQPCTLALDH1A1HRH3MEN1 | |
| SCHEMBL18381238 | 0.81 | CYP3A4 (0.65) | QPCTQPCTLALDH1A1HRH3MEN1 | |
| SCHEMBL21048485 | 0.80 | TSHR (0.47) | QPCTQPCTLHRH3HRH4CYP3A4 | |
| SCHEMBL1641207 | 0.80 | QPCT (0.62) | QPCTQPCTLALDH1A1HRH3MEN1 | |
| SCHEMBL14586424 | 0.79 | QPCT (0.57) | QPCTQPCTLALDH1A1HRH3MEN1 | |
| SCHEMBL1527998 | 0.78 | TBXAS1 (0.72) | QPCTQPCTLALDH1A1HRH3MAPT | |
| SCHEMBL2755873 | 0.77 | QPCT (0.71) | QPCTQPCTLALDH1A1HRH3MEN1 | |
| SCHEMBL17040362 | 0.77 | TBXAS1 (0.56) | QPCTQPCTLALDH1A1HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943494-B1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | LILLY CO ELI (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2943494-B1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | LILLY CO ELI (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2943494-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | Eli Lilly and Company (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969555-B2 | Bicyclic pyrimidine compounds | ELI LILLY AND COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140200231-A1 | Bicyclic Pyrimidine Compounds | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200231-A1 | Bicyclic Pyrimidine Compounds | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014110000-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014110000-A1 | PYRIDO- OR PYRROLO-FUSED PYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-1242074-A4 | 5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1242074-A1 | 5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6369076-B1 | ANALGESICS | MERCK & CO. INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2001032171-A1 | 5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200231-A1 | Bicyclic Pyrimidine Compounds | ENPP2, HAX1, NUDT1 | QPCT 77/4885QPCTL 660/4885ALDH1A1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.